

Docket No. 000364.00124

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Juerg Lareida
SERIAL NO: Unknown
FILED: Concurrently Herewith
FOR: Medicament for Treatment of Neuropathies

GAU:
EXAMINER:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a copy of applicant's pending application(s) or issued patent(s) which may be related to the present application. These documents are listed on form PTO-1449, also attached.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in any counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited for the first time in any communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.
- ☒ This Information Disclosure Statement is being filed within three months of the filing date of the subject patent application.
- ☐ This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.

PETITION

- ☐ Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR §1.17(i)(1).


DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 23-2185. A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

BLANK ROME COMISKY & MCCAULEY LLP

THE FARRAGUT BUILDING
SUITE 1000
900 17TH STREET, NW
WASHINGTON, DC 20006
TEL (202) 530-7400
FAX (202) 463-6915


Herbert Cohen
Attorney of Record
Registration No. 25,109



27557

PATENT TRADEMARK OFFICE

Date: March 15, 2002

08/01

Form PTO 1449
 (Modified)

U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
 000364.00124

SERIAL NO.
 Unknown

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT Juerg Lareida

FILING DATE
 Concurrently Herewith
 U.S. PATENT DOCUMENTS

GROUP

EXAMINER INITIAL	DOC. NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA	4,666,908	1987	Hamilton	514	229	
AB	6,075,028	2000	Graham	514	258	
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						
AM						
AN						

FOREIGN PATENT DOCUMENTS

DOC. NUMBER	DATE	COUNTRY	TRANSLATION YES	NO
X AO WO 93/07149	1993	WIPO	<input checked="" type="checkbox"/>	<input type="checkbox"/>
AP			<input type="checkbox"/>	<input type="checkbox"/>
AQ			<input type="checkbox"/>	<input type="checkbox"/>
AR			<input type="checkbox"/>	<input type="checkbox"/>
AS			<input type="checkbox"/>	<input type="checkbox"/>
AT			<input type="checkbox"/>	<input type="checkbox"/>
AU			<input type="checkbox"/>	<input type="checkbox"/>
AV			<input type="checkbox"/>	<input type="checkbox"/>

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

AW	Rendell et al., Sildenafil for Treatment of Erectile Dysfunction in Men With Diabetes, XP-000986570 - JAMA, Journal of the Americal Medical Association, Vol. 281, No. 5, 1999
AX	Zesiewicz et al., Sildenafil Citrate (Viagra) for the Treatment of Erectile Dysfunction in Men with Parkinson's Disease, XP-000989552- Neurology, Bd. 52, Nr. 6, 1999
AY	Brewer et al., Sildenafil Citrate Therapy in Men with Parkinson's Disease, XP-000991091 - Movement Disorders, Bd. 13, Nr. 5, 1998
AZ	Nurnberg et al., Sildenafil for Iatrogenic Serotenergic Antidepressant Medication-Induced Sexual Dysfunction in 4 Patients, SP-00987161 - Journal of Clinical Psychiatry, Nd. 60. Nr. 1, 1999
AZZ	Swope et al., Preliminary Report: Use of Sildenafil to Treat Dyskinesias in Patients with Parkinson's Disease, SP-002162785 - Neurology, Bd. 54, Nr. 7, 2000

Date Considered

Examiner

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.